Clinical Study

Iov-Lun-202- A Phase 2 Multicenter Study Of Autologous Tumor Infiltrating Lymphocytes (Ln-145) In Patients With Metastatic Non-Small-Cell Lung Cancer

Posted Date: Apr 28, 2021

  • Investigator: Jennifer Leddon
  • Specialties: Cancer, Lung Cancer, Oncology
  • Type of Study: Drug

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic NSCLC using objective response rate.

Criteria:

Confirmed Histologic Diagnosis Of Non-Small-Cell Lung Carcinoma, At Least 1 Resectable Lesion. Previously Irradiated Lesion Must Have Radiographic Progression Prior To Harvest, Ecog 0-1, No Prior Malignancy Within 3 Years, No Symptomatic And/Or Untreated Brain Metastases, No Primary Immunodeficiency, No History Of Organ Transplant In 20 Years

Keywords:

Lung Cancer, Nsclc

For More Information:

Uc Cancer Center
513-584-7658
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.